You are about to leave the Clinical Value website now.
Cancel
Continue
Home / Events / Tailoring Treatment: A Deep Dive into ALK+ mNSCLC Management in Asian Populations
Tailoring Treatment: A Deep Dive into ALK+ mNSCLC Management in Asian Populations
Supported by:
In this webinar, you can expect to,
Explore the Long-Term Impact of ALK Inhibitors: From Clinical Trials to Real-World Evidence
Overall Survival (OS) Improvements: Gain groundbreaking insights into long-term OS outcomes as we present the latest findings from the 7-year ALESIA data updates.
Real-World Case Insights: Understand how ALK inhibitor demonstrates significant survival benefits and a favourable safety profile, with a focus on Asian subgroups.
Learn more about biomarker testing: Comprehensive molecular testing is essential for the effective management of NSCLC, particularly for guiding targeted therapies. By implementing an integrated and efficient testing strategy, clinicians can better personalise treatment plans, optimise outcomes, and manage resources effectively
Professor Caicun Zhou is a distinguished Chief Physician, Professor, and Doctoral Supervisor at Shanghai East Hospital, where he also serves as the Director of the Oncology Institute within Tongji University School of Medicine. Prof. Zhou is the President-Elect of the Board of Directors for the International Association for the Study of Lung Cancer, exemplifying his global leadership in oncology research. Within China, Prof. Zhou chairs several prominent committees, including the Chest Tumor Branch of the China International Exchange and Promotive Association for Medical and Health Care, and the Non-small Cell Lung Cancer Expert Committee of the Chinese Society of Clinical Oncology. Additionally, he heads the Anti-tumor Drug Clinical Research Committee at the China Anti-cancer Association and the Lung Cancer Molecular Targeted Therapy and Immunotherapy Committee under the Shanghai Anticancer Association. Prof. Zhou’s extensive expertise and leadership in lung cancer and oncology significantly advance both clinical research and the development of innovative cancer treatments.
Prof. Sung Yong Lee is a distinguished professor and the Chief of the Division of Pulmonary, Allergy, and Critical Care Medicine at Korea University Guro Hospital. He earned his MD from Korea University College of Medicine in 1995, followed by a Master’s and Ph.D. in 2000 and 2006, respectively. Prof. Lee completed his internship and residency in Internal Medicine at Korea University and served as a clinical instructor and assistant professor in pulmonology before advancing to an associate professor role in 2009. He expanded his expertise as a Research Fellow in Pathology at Johns Hopkins University (2011-2013). Currently, he leads his division with a focus on advancing pulmonary and critical care. An active member of multiple prestigious societies, including the Korean Society of Internal Medicine and the International Association for the Study of Lung Cancer, Prof. Lee is highly respected in the fields of pulmonology and respiratory research.
Assoc. Prof. Thanyanan Baisamut (Ruengwettwattana)
Assoc. Prof. Thanyanan Baisamut (Ruengwettwattana)
Ramathibodi Hospital Thailand
Associate Professor Thanyanan Baisamut (Reungwetwattana), M.D., M.Sc. is a renowned medical oncologist at the Medical Oncology Unit, Department of Medicine, Ramathibodi Hospital, Thailand. With extensive expertise in thoracic malignancies and cancer drug development, she has made significant contributions through both clinical practice and research. Dr. Thanyanan’s work focuses on personalised medicine and the molecular characterization of lung cancer. She has been a leader in various prestigious clinical trials and has collaborated internationally, earning recognition for her innovative approaches in oncology.
Professor Ngan is currently Clinical Professor of the Department of Clinical Oncology, School of Clinical Medicine, HKUMed, and the Chief of Specialty in Oncology at Gleneagles Hospital Hong Kong. He is also an Honorary Consultant in the Departments of Clinical Oncology of both Queen Mary Hospital and Queen Elizabeth Hospital, and in the Department of Surgery of Kwong Wah Hospital, Hong Kong. He is the Chairperson of the Governing Committee of the Cancer Research Laboratory of Queen Elizabeth Hospital of Hong Kong.
Professor Ngan is a specialist in clinical oncology practising in Hong Kong who has a special interest in the clinical research of multimodality management of head and neck cancers, breast cancers, gynaecological cancers, soft tissue sarcomas and brachytherapy. He has published more than 150 articles in peer-reviewed journals and book chapters.
Professor Ngan has worked as the Director of the Hong Kong Cancer Registry from 2012-2018, and the Chief of Service of the Department of Clinical Oncology, Queen Elizabeth Hospital from 2013-2018. He is a Council Member of the Hong Kong Head and Neck Society, the Immediate Past President of the Hong Kong Breast Oncology Group, and Deputy Chief Editor of the Hong Kong Journal of Radiology.
Agenda
Time (GMT+8)
Topic
Speakers
18:00 - 18:05
Opening
Prof. Caicun Zhou
Shanghai East Hospital, China
18:05 - 18:25
Optimal testing approaches in Asia Pacific region for non-small cell lung cancer patients
Prof. Sung Yong Lee
Korea University Guro Hospital, Korea
18:25 - 18:40
7 years of Progress: ALESIA Study’s impact on ALK+ advanced NSCLC Patient outcomes.
Assoc. Prof. Thanyanan Baisamut (Ruengwettwattana)
Ramathibodi Hospital, Thailand
18:40 - 19:00
Clinical case sharing: ALK+ advanced NSCLC patient management
Prof. Roger Ngan Gleneagles Hospital, Hong Kong
19.00-19.15
Q&A
All
Date:
13th December 2024
Time:
18:00 - 19:15
(GMT+08:00)
15:00 - 16:15
(Karachi)
15:30 - 16:45
(Delhi)
17:00 - 18:15
(Bangkok / Ho Chi Minh / Jakarta)
19:00 - 20:15
(Seoul / Tokyo)
This material represents personal viewpoint and is intended to
promote the communication and exchange of medical information, and
shall be used by healthcare professionals as a reference only.
This material may contain medicinal products or clinical
indications that have not yet been approved in your country.
Please refer to the locally approved package insert for detailed
prescription information.
Be the first to receive updates, event opportunities, and thought leadership insights.
The information contained in this website is intended for healthcare professionals only.
Click “OK” if you are a healthcare professional.
